Ovarian Cancer | Specialty

The OncLive Ovarian Cancer condition center page is a comprehensive resource for clinical news and expert insights on ovarian cancer and evolving treatment approaches, including PARP inhibitors, antibody-drug conjugates, chemotherapy and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in ovarian cancer.

Raludotatug Deruxtecan Demonstrates Promising Efficacy, Safety in Platinum-Resistant Ovarian Cancer

October 20th 2025

Raludotatug deruxtecan demonstrates antitumor activity and manageable safety in platinum-resistant ovarian cancer.

Chemotherapy Plus Durvalumab, Bevacizumab, and Olaparib Fails to Offer OS Benefit in Newly Diagnosed Non-tBRCA–Mutated Ovarian Cancer

October 19th 2025

Chemotherapy plus durvalumab, bevacizumab, and olaparib did not significantly prolong OS in non-tBRCA-mutated ovarian cancer.

Relacorilant Plus Nab-Paclitaxel Yields PFS Advantage in PARP Inhibitor–Exposed PROC

October 19th 2025

The addition of relacorilant to nab-paclitaxel produced a PFS benefit vs nab-paclitaxel alone in PROC with a history of PARP inhibitor exposure.

TUB-040 Yields Responses Across Dose Levels in Platinum-Resistant High-Grade Serous Ovarian Cancer

October 19th 2025

NAPISTAR1-01 showed enduring benefit with TUB-040 in patients with platinum-resistant high-grade serous ovarian cancer.

Pembrolizumab Plus Paclitaxel +/– Bevacizumab Yields Survival Advantages in Recurrent PROC

October 18th 2025

Pembrolizumab and paclitaxel with or without bevacizumab led to PFS and OS benefits vs placebo in place of pembrolizumab in recurrent, PD-L1–positive PROC.

Dr Elias on the Role of Olaparib Maintenance Therapy For BRCA1/2-Mutated Ovarian Cancer

October 17th 2025

Kevin Elias, MD, discusses the role of olaparib maintenance therapy for patients with BRCA1 and BRCA2-mutated ovarian cancer.

Pembrolizumab Plus Chemo With or Without Bevacizumab Improves OS in Platinum-Resistant Ovarian Cancer

October 16th 2025

Pembrolizumab plus chemotherapy with or without bevacizumab improved overall survival in platinum-resistant ovarian cancer.

Dr Lynam on the Importance of FRα Expression Testing in Ovarian Cancer

October 15th 2025

Sarah Lynam, MD, highlights the importance of folate receptor–alpha expression testing to inform treatment decision-making in patients with ovarian cancer.

EU Approval Sought for Relacorilant in Platinum-Resistant Ovarian Cancer

October 14th 2025

The approval of relacorilant for use in patients with platinum-resistant ovarian cancer is sought from the European Medicines Agency.

Oncology Experts Preview Key Studies Ahead of the 2025 ESMO Congress

October 13th 2025

Leading experts across oncology specialties preview the key studies and data they are most anticipating ahead of the 2025 ESMO Congress.

Olaparib Withstands the Test of Time With Long-Term Data Supporting Its Role in Ovarian Cancer Treatment

October 13th 2025

Kevin Elias, MD, discusses the role of olaparib in the management of ovarian cancer.

Dr Elias on Efficacy Data With Olaparib in BRCA-Mutated Ovarian Cancer

October 10th 2025

Kevin Elias, MD, discusses the SOLO-1 and SOLO-2 trials, which evaluated olaparib in newly diagnosed and relapsed BRCA-mutated ovarian cancer.

Poll Results Highlight Gynecologic Oncology Abstracts to Watch Ahead of ESMO 2025

October 10th 2025

See poll results highlighting the top gynecologic oncology abstracts and subtypes to watch at the 2025 ESMO Congress.

Dr Lynam on the Significance of Mirvetuximab Soravtansine in Ovarian Cancer

October 8th 2025

Sarah Lynam, MD, discusses the significance and implications of mirvetuximab soravtansine for the treatment of patients with ovarian cancer.

CDK4/6 Inhibition With Palbociclib Displays Activity in Low-Grade Serous Ovarian Cancer

October 7th 2025

CDK4/6 inhibition with palbociclib demonstrated encouraging efficacy in patients with low-grade serous ovarian cancer.

Poll: Vote on the Top Gynecologic and GI Cancer Abstracts/Topics to Watch at ESMO 2025

October 6th 2025

Vote on the top abstracts and topics to watch in gynecologic and gastrointestinal oncology during the 2025 ESMO Congress.

Advances in Targeted Therapies and ADCs in Gynecologic Cancer Are Highly Anticipated at the 2025 ESMO Congress

October 1st 2025

Experts in the gynecologic cancer landscape highlight their most anticipated presentations ahead of the 2025 ESMO Congress.

Stenoparib Monotherapy Yields Potential OS Benefit in Platinum-Resistant Ovarian Cancer

September 26th 2025

Stenoparib monotherapy generated long-term clinical benefit in patients with platinum-resistant and -refractory advanced ovarian cancer.

Avantect Multi-Cancer and Ovarian Cancer Detection Tests Achieve UKCA Marking

September 25th 2025

A United Kingdom Conformity Assessed marking was granted to the Avantect Multi-Cancer Detection Test and Avantect Ovarian Cancer Test.

Five Under 5: Top Oncology Videos for the Week of 9/14

September 21st 2025

The top 5 OncLive TV videos of the week cover insights in lung cancer, multiple myeloma, and ovarian cancer.